Чехія - чеська - SUKL (Státní ústav pro kontrolu léčiv)

belupo, s.r.o., bratislava array - 2065 betamethason-dipropionÁt; 656 gentamicin-sulfÁt - mast - 0,5mg/g+1mg/g - betamethason a antibiotika

Чехія - чеська - SUKL (Státní ústav pro kontrolu léčiv)

b. braun melsungen ag, melsungen array - 12307 rokuronium-bromid - injekční/infuzní roztok - 10mg/ml - rokuronium-bromid

Чехія - чеська - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi s.r.o., praha array - 12307 rokuronium-bromid - injekční/infuzní roztok - 10mg/ml - rokuronium-bromid

Чехія - чеська - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 16335 aprepitant; 16335 aprepitant - tvrdá tobolka - 80mg+125mg - aprepitant

Чехія - чеська - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 16335 aprepitant; 16335 aprepitant - tvrdá tobolka - 125mg+80mg - aprepitant

Чехія - чеська - SUKL (Státní ústav pro kontrolu léčiv)

teva b.v., haarlem array - 16335 aprepitant; 16335 aprepitant - tvrdá tobolka - 125mg+80mg - aprepitant

Європейський Союз - чеська - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastická činidla - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Європейський Союз - чеська - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - další antineoplastické látky - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Європейський Союз - чеська - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Європейський Союз - чеська - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresiva - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).